| Literature DB >> 27857183 |
Izabela Zawlik1,2, Ewa Kaznowska1,3, Jozef Cebulski4, Magdalena Kolodziej5,6, Joanna Depciuch7, Jitraporn Vongsvivut8, Marian Cholewa4.
Abstract
Triple-negative breast cancer is the most aggressive breast cancer subtype with limited treatment options and a poor prognosis. Approximately 70% of triple-negative breast cancer patients fail to achieve a pathologic complete response (pCR) after chemotherapy due to the lack of targeted therapies for this subtype. We report here the development of a focal-plane-array Fourier transform infrared (FPA-FTIR) microspectroscopic technique combined with principal component analysis (PCA) for monitoring chemotherapy effects in triple-negative breast cancer patients. The PCA results obtained using the FPA-FTIR spectral data collected from the same patients before and after the chemotherapy revealed discriminatory features that were consistent with the pathologic and clinical responses to chemotherapy, indicating the potential of the technique as a monitoring tool for observing chemotherapy efficacy.Entities:
Mesh:
Year: 2016 PMID: 27857183 PMCID: PMC5114655 DOI: 10.1038/srep37333
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1H&E images of breast cancer tissues obtained using tru-cut needle biopsy before (A) and after (B) chemotherapy. Arrows on images 53A, 56A and 50A indicate the presence of cancer tissue before chemotherapy. After chemotherapy, image 53B reveals a complete pathologic response after chemotherapy (i.e. no cancer cells detected in specimen). Image 56B represents the specimen after chemotherapy with partial pathologic response showing a presence of microfocus of residual cancer tissue, while image 50B indicates only minimal pathologic response evidenced by the residual cancer cells that exhibited increased cytologic changes and marked stromal fibrosis.
Figure 2Schematic illustration of spectral pre-processing approach including (A) microscopic images of H&E stained sections used for selecting the regions of interest for spectral data collection, (B) FTIR chemical images of protein distribution using integrated area under amide I band (1710–1600 cm−1), and (C) their corresponding FTIR chemical images after quality test using S/N ratio criterion of 100.
Figure 3Representative EMSC-corrected 2nd derivative spectra of the breast tissues collected from Patient No. 50, 53, 56 and 01–04 observed before and after chemotherapy.
Assignment of the major bands that possessed a significant influence on the PCA discrimination.
| Wavenumber (cm−1) | Band Assignment |
|---|---|
| 1654 | amide I: α-helix |
| 1462 | δscissor(CH2) from methylene (–CH2) groups in acyl chains of lipid bilayers in orthorhombic packing |
| 1411 | δrock(CH2) of disubstituted |
| 1049 | ν(C–O) coupled with δ(C–O) of C–OH groups of carbohydrates mainly from glycogen |
Figure 4Corresponding PCA scores plot obtained using prior FPA-FTIR spectral data of the breast tissues collected from Patient No. 50, 53, 56 and 01–04 before and after chemotherapy, showing the discrimination patterns as a result of changes in biological compositions that were observed through FTIR spectral features in the regions of 1800–1500 and 1420–925 cm−1.
Clinicopathological characteristics of breast cancer patients.
| Case No. | Age | Race | Histological Type | Grade | Clinical staging before preoperaive chemotherapy | Preoparative chemotherapy | Pathological response | Type of surgery | Long-term follow-up |
|---|---|---|---|---|---|---|---|---|---|
| 53 | 36 | White | Ductal Carcinoma | G3 | cT2N1 | AT3s - 3 series Adria 85 mg, Taxotere 130 mg | ypT0N0 | Mastectomia m.Madden | Alive without recurrence or metastases |
| 56 | 51 | White | Ductal Carcinoma | G3 | cT2N1 | FAC6s - 6 series Flu745mg, Adria 74 mg, CTX 745 mg | ypT1aN0 | Mastectomia m.Madden | Alive without recurrence or metastases |
| 50 | 63 | White | Ductal Carcinoma | G2 | cT2N2 | AT6s - 6 series Adria 90 mg, Taxotere 160 mg | ypT2N2a | Mastectomia m.Madden | Death in 2 years after surgery, spine and lung metastases |
| 01 | 31 | White | Ductal Carcinoma | G3 | cT3N2 | AT6s - 5 series Adria 80 mg, Taxotere 150 mg | ypT1bNx | Mastectomia m.Madden | Alive without recurrence or metastases |
| 02 | 74 | White | Ductal Carcinoma | G2 | cT2N2 | AT6s - 6 series Adria 90 mg, Taxotere 160 mg | ypT1aN1a | Mastectomia m.Madden | Alive without recurrence or metastases |
| 03 | 54 | White | Ductal Carcinoma | G2 | cT2N2 | FAC 6 series 5Fu-650mg, Adria-65mg, CTX-650mg | ypT1aNx | Mastectomia m.Madden | Alive without recurrence or metastases |
| 04 | 39 | White | Ductal Carcinoma | G1 | cT2N1 | AT 6 series Adria - 75 mg, Taxotere – 115 mg | ypT2N3a | Mastectomia m.Madden | Alive without recurrence or metastases |